-- 劳氏船级社周一宣布,已与韩国釜山国立大学合作,共同创建首个国际认可的液氢运输船联合性能评估和认证框架。 声明指出,由于缺乏测试和验证标准,氢燃料在海运领域的应用进展有限。 劳氏船级社表示,氢燃料具有特殊的技术要求,包括在零下253摄氏度的低温下储存,这需要非常特殊的材料、密封系统和安全措施。 声明称,新的框架将“为评估性能、安全性和可靠性提供一致且全球适用的基础,有助于减少项目设计和审批阶段的不确定性”。 声明还补充道,该框架将结合劳氏船级社在海事分类和认证方面的专业知识以及釜山国立大学在低温工程领域的研究成果。 这将为船舶和密封项目的早期阶段提供指导,帮助其从概念阶段过渡到审批和建造阶段。 双方将评估储罐及相关管道的低温和绝缘性能,检查其在负载下的结构完整性,进行安全和风险评估,并制定海洋环境的测试方法和认证程序。
Related Articles
Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%
Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.
ASX Biggest Losers
Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07
Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal
Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.